PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K ATP channel openers with other drugs to treat diseases of humans and animals.
1 .- 20 . (canceled)
21 . A method of preventing the transition to diabetes of a prediabetic individual, comprising administering to the individual a pharmaceutical formulation comprising a therapeutically effective amount of diazoxide no more than two times per 24 hours.
22 . The method of claim 21 wherein said administering is once per 24 hours.
23 . The method of claim 21 , wherein the pharmaceutical formulation is a controlled release formulation and the controlled release occurs over a time period of 8-24 hours following administration.
24 . The method of claim 21 , wherein between 100 and 200 mg of diazoxide is administered per dose.
25 . The method of claim 21 , wherein between 200 and 300 mg of diazoxide is administered per dose.
26 . The method of claim 21 , wherein between 300 and 500 mg of diazoxide is administered per dose.
27 . A method of restoring normal glucose tolerance to a diabetic individual comprising administering to the individual a therapeutically effective amount of diazoxide.
28 . The method of claim 27 wherein said administering is once per 24 hours.
29 . The method of claim 27 , wherein the pharmaceutical formulation is a controlled release formulation and the controlled release occurs over a time period of 8-24 hours following administration.
30 . The method of claim 27 , wherein between 100 and 200 mg of diazoxide is administered per dose.
31 . The method of claim 27 , wherein between 200 and 300 mg of diazoxide is administered per dose.
32 . The method of claim 27 , wherein between 300 and 500 mg of diazoxide is administered per dose.
33 . A method of treating dyslipidemia or impaired glucose tolerance in an individual treated with an anti-psychotic drug, comprising administering to the individual a therapeutically effective amount of diazoxide.
34 . The method of claim 33 wherein said administering is once per 24 hours.
35 . The method of claim 33 , wherein the pharmaceutical formulation is a controlled release formulation and the controlled release occurs over a time period of 8-24 hours following administration.
36 . The method of claim 33 , wherein between 100 and 200 mg of diazoxide is administered per dose.
37 . The method of claim 33 , wherein between 200 and 300 mg of diazoxide is administered per dose.
38 . The method of claim 33 , wherein between 300 and 500 mg of diazoxide is administered per dose.